| Literature DB >> 32728352 |
Edward J Calabrese1, Aristidis Tsatsakis2, Evgenios Agathokleous3, James Giordano4, Vittorio Calabrese5.
Abstract
Green tea, and its principal constituent (-)-epigallocatechin-3-gallate (EGCG), are commonly shown to induce biphasic concentration/dose responses in a broad range of cell types, including non-tumor cells, and tumor cell lines. The most active area of research dealt with an assessment of neural cells with application to neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease cell models, often using preconditioning experimental protocols. The general findings demonstrate EGCG-induced hormetic effects resulting in an enhanced acquired resilience within an adaptive and temporally dependent homeodynamic framework. The biphasic dose responses displayed the typical quantitative features of the hormetic dose response with respect to the amplitude and width of the stimulatory response. These findings provide further evidence for the general occurrence of hormetic dose responses with such responses being independent of the biological model, end point, inducing agent, and mechanism. The biphasic nature of these responses has important implications since it suggests optimal dose ranges for end points of public health and therapeutic applications. These findings indicate the need to assess the entire dose-response continuum in order to better define the nature of the dose response, especially in the low-dose zone where such exposures are common in human populations.Entities:
Keywords: EGCG; biphasic dose response; dose response; green tea; hormesis; preconditioning
Year: 2020 PMID: 32728352 PMCID: PMC7364811 DOI: 10.1177/1559325820936170
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
Figure 1.Dose-response curve showing the quantitative features of hormesis.[17]
Hormetic Mechanisms for Green Tea and (–)-Epigallocatechin-3-Gallate.
| Mechanisms |
|---|
| Nonneuronal and non-tumor cells |
|
|
| 2) TPH-1 cell macrophages—EGCG blocked uptake of ricin by cells, preventing toxicity[ |
| 3) HepG2 cells—preventing Pb toxicity mechanism. Free radical scavenging, heavy metal chelation, prevents lipid membrane oxidation[ |
|
|
| 5) Retinal pigment epithelial cells (RPE)—The low dose stimulation was potentially harmful; no mechanism was provided; mechanisms were offered for high dose inhibitory response[ |
| 6) Protection of cells was mediated via activation of Akt signaling and suppression of the P38 JNK pathway[ |
| PC12 cells |
| 7) EGCG inhibited NFkB nuclear translocation and binding by 6-OHDA in SH-SY5Y cells. EGCG enhanced iron chelation, which prevented nuclear translocation and activation of cell death from NF-kB[ |
| 8) Protection resulted from maintaining proper mitochondria functioning, preventing apoptosis via the inhibition of caspase 3 activation and down regulated the expression of the pro-apoptosis protein 5Mac in the cytosol[ |
| 9) EGCG potentiates the neuritogenic effects of BDNF via the involvement of 67-kDa laminin receptor and H2O2.[ |
| 10) EGCG prevented the down regulation of Shh signaling of corticosterone. EGCG pretreatment reduced Cort-induced down regulation of Gli1 and N-myc, suggesting that EGCG may activate the Shh signaling pathways.[ |
| SH-SY5Y cells |
| 11) EGCG reversed the occurrence of 6-OHDA-induced decrease of STAT-3 activity.[ |
| Hippocampal neurons |
| 12) The EGCG pretreatment protection against corticosterone-induced toxicity was blocked by the pharmacological inhibitors for ERK1/2 (00126) and P13k/Akt (LY294002).[ |
| 13) EGCG enhances neuronal survival and neuronal differentiation of adult hippocampal precursor cells, which was absent, when P13 k, a protein upstream of Akt, was blocked[ |
Figure 2.Effects of green tea polyphenols (GTPP) on the cellular generation of reactive oxygen species (ROS) on PC12 cells.[63]
Figure 3.Hormetic concentration range across multiple tumor cell types. Data for each tumor cell response is provided in Figure S8—HuLM; Figure S14—Colo205; Figure S6—INT-407; Figure S9—Prostate and Ovarian; Figure S10—REN-mesothelioma; Figure S7—SCC-25.
Figure 4.Hormetic concentration range across multiple non-tumor cell types. Data for each cell type are provided in Figure S20—Pancreatic α cell; Figure S21—THP-1; Figure S19—INS; Figure S18—RPE; Figure S13—NCM460; Figure S16—HepG2.
Figure 5.Hormetic concentration range across PC12 cells. Data for each dose response are provided in Figure S37—EGCG; Figure S31—GT 6-OHDA CV and BT 6-OHDA; Figure S39—GTPP; Figure S34—Paraquet CV; Figure S38—Corticosterone CV; Figure S29—Corticosterone PC; Figure S35—L-Dopa CV; Figure S36—EGCG-AB1-42.
Figure 6.Hormetic concentration range across SH-SY57 cells. Data for each dose response are provided in Figure S23—EGCG LDH; Figure S24—EGCG CV 6-OHDA; Figure S25—EGCG and EGCG CV AB; Figure S32—GT CV 6-OHDA.